| Heffernan, Michael P |
| Completed | 3 | 226 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 09/24 | 09/24 | | |
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF |
|
|
| Terminated | 3 | 1238 | Canada | Rivaroxaban, Xarelto, standard of care | Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation | ATRIAL FIBRILLATION | 05/24 | 05/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Verma, Subodh |
| Recruiting | 4 | 396 | Canada | a wearable adhesive cardiac monitoring device | St. Michael's Hospital, Toronto, Southlake Regional Health Centre, University Health Network, Toronto | Cardiac Arrhythmias, Atrial Fibrillation | 12/20 | 12/20 | | |
| Completed | 4 | 169 | Canada, RoW | Empagliflozin, Jardiance, Placebo | Unity Health Toronto, Canadian Medical and Surgical Knowledge Translation Research Group, Boehringer Ingelheim, Applied Health Research Centre | Cardiovascular Diseases, Left Ventricular Hypertrophy | 07/22 | 07/22 | | |
| Completed | 4 | 70 | Canada | Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Vascepa, IPE | Canadian Medical and Surgical Knowledge Translation Research Group, HLS Therapeutics, Inc, Unity Health Toronto, Western University, Canada | Cardiovascular Diseases, Cardiovascular Risk Factor, Triglycerides High, Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
| Recruiting | 4 | 766 | Canada, US | Evolocumab, Repatha®, Placebo, Control | Unity Health Toronto, Applied Health Research Centre | Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion | 12/23 | 12/23 | | |
| Recruiting | 4 | 100 | Canada | Semaglutide Pen Injector, Ozempic, Wegovy | Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, Western University, Canada | Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity | 12/24 | 12/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Completed | 2 | 204 | Europe, Canada, Japan, US, RoW | LY3561774, Placebo | Eli Lilly and Company | Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia | 03/24 | 05/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
NCT05271591: Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA) |
|
|
| Completed | N/A | 200 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group, HLS Therapeutics, Inc | Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Myocardial Infarction, Coronary Heart Disease | 04/22 | 04/22 | | |
| Completed | N/A | 120 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, Western University, Canada | Diabetes, Type 1 Diabetes, Type 2 Diabetes, Ischemic Heart Disease, Ischemic Stroke, Cardiovascular Diseases, Peripheral Vascular Diseases | 01/23 | 01/23 | | |
| Recruiting | N/A | 40 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group | Peripheral Vascular Diseases, Cardiovascular Disease, Type 2 Diabetes, Peripheral Artery Disease | 07/25 | 07/25 | | |
| Recruiting | N/A | 40 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group | Cardiovascular Diseases, Atherosclerosis Cardiovascular Disease, Ischemic Heart Disease, Dyslipidemia | 07/25 | 07/25 | | |
ORIGINS-VRCE-2, NCT06769347: Circulating Vascular Regenerative Cell Exhaustion in Individuals Without Type 2 Diabetes Who Are of South Asian or European Origins |
|
|
| Not yet recruiting | N/A | 120 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, Western University, Canada | Cardiovascular Diseases Risk | 01/29 | 01/29 | | |
FIERCE, NCT06108388: Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion |
|
|
| Not yet recruiting | N/A | 90 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, University of Western Ontario, Canada | Diabetes Mellitus, Type 2 | 12/25 | 06/26 | | |
NCT05427370: The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C) |
|
|
| Recruiting | N/A | 754 | Europe, Canada, US, RoW | Revascularization by PCI, Revascularization by CABG | Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR), Weill Medical College of Cornell University | Coronary Artery Disease, Heart Failure Systolic | 04/29 | 12/29 | | |
| Not yet recruiting | N/A | 30 | Canada | | Canadian Medical and Surgical Knowledge Translation Research Group | Polycystic Ovary Syndrome | 02/23 | 04/23 | | |
| Nakamura, Masahiko |
NCT04609059: First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation |
|
|
| Recruiting | 2 | 42 | Japan | M201-A Injection, Placebo | Kitasato University, Aetas Pharma Co., Ltd. | Paroxysmal Atrial Fibrillation | 10/19 | 12/20 | | |
| Umetani, Ken |
NCT04609059: First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation |
|
|
| Recruiting | 2 | 42 | Japan | M201-A Injection, Placebo | Kitasato University, Aetas Pharma Co., Ltd. | Paroxysmal Atrial Fibrillation | 10/19 | 12/20 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Burstein, Jason |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Paolino, Bruno |
| Completed | 3 | 507 | RoW | Dapagliflozin 10mg Tab, Farxiga, Standard of Care | Hospital Israelita Albert Einstein | Critical Illness, Sepsis | 10/23 | 10/23 | | |
NEOMINDSET, NCT04360720: PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial |
|
|
| Recruiting | 3 | 3400 | RoW | Antiplatelet Monotherapy | Hospital Israelita Albert Einstein | Acute Coronary Syndrome | 01/24 | 01/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Yip, Amelia |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
